Lactoferrin için Recurrent Infections

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Sonuç

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg vs: Placebo Outcome: Disease remission Etki: None None

Popülasyon: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None vs: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus Etki: None None

Popülasyon: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None vs: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease Etki: Decreased defensin and LL-37 in Crohn's patients None

Popülasyon: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None vs: None Outcome: immune function Etki: None None

Popülasyon: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg vs: baseline Outcome: oxidative stress markers Etki: or 2 None

Popülasyon: general population

Key Statistics

Çalışmalar

2000

Katılımcılar

↑

Positive

Derece

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 atıf

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 atıf

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 atıf

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 atıf

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 atıf

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 atıf

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 atıf

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

Üst sınır: No established UL; well-tolerated up to 1,200 mg/day

Araştırmalarda İncelenen Dozajlar

Dozaj	Süre	Etki	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

En iyi alım zamanı: On empty stomach

Safety & Side Effects

Bildirilen Yan Etkiler

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

Bilinen Etkileşimler

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

Tolere edilebilir üst alım: No established UL; well-tolerated up to 1,200 mg/day

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Recurrent Infections

Bovine Colostrum B

Hızlı Değerlendirme

Evidence Strength92%

High confidence

Çalışma Dağılımı

RCT (1)Meta (0)Other (7)

Alternatifleri Karşılaştır

Bu durum için diğer bileşenlerin nasıl karşılaştırıldığını görün.Diğer içeriklerin bu sağlık durumu için nasıl karşılaştırıldığını görün.

Şu durum için tüm içerikleri görüntüle: Recurrent Infections

Daha Fazla Bilgi

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.